These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 17116003

  • 1. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.
    Lundåsen T, Gälman C, Angelin B, Rudling M.
    J Intern Med; 2006 Dec; 260(6):530-6. PubMed ID: 17116003
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Chenodeoxycholic Acid Modulates Bile Acid Synthesis Independent of Fibroblast Growth Factor 19 in Primary Human Hepatocytes.
    Johansson H, Søndergaard JN, Jorns C, Kutter C, Ellis ECS.
    Front Endocrinol (Lausanne); 2020 Dec; 11():554922. PubMed ID: 33692750
    [Abstract] [Full Text] [Related]

  • 6. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
    Friedrich D, Marschall HU, Lammert F.
    BMC Gastroenterol; 2018 Jun 04; 18(1):76. PubMed ID: 29866129
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Diurnal variations of mouse plasma and hepatic bile acid concentrations as well as expression of biosynthetic enzymes and transporters.
    Zhang YK, Guo GL, Klaassen CD.
    PLoS One; 2011 Feb 08; 6(2):e16683. PubMed ID: 21346810
    [Abstract] [Full Text] [Related]

  • 9. A nontumorigenic variant of FGF19 treats cholestatic liver diseases.
    Luo J, Ko B, Elliott M, Zhou M, Lindhout DA, Phung V, To C, Learned RM, Tian H, DePaoli AM, Ling L.
    Sci Transl Med; 2014 Jul 30; 6(247):247ra100. PubMed ID: 25080475
    [Abstract] [Full Text] [Related]

  • 10. Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis.
    Li Z, Lin B, Lin G, Wu Y, Jie Y, Li X, Ko B, Chong Y, Luo J.
    PLoS One; 2017 Jul 30; 12(6):e0178580. PubMed ID: 28570655
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass.
    Gerhard GS, Styer AM, Wood GC, Roesch SL, Petrick AT, Gabrielsen J, Strodel WE, Still CD, Argyropoulos G.
    Diabetes Care; 2013 Jul 30; 36(7):1859-64. PubMed ID: 23801799
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Regulation of bile acid metabolism in biliary atresia: reduction of FGF19 by Kasai portoenterostomy and possible relation to early outcome.
    Johansson H, Svensson JF, Almström M, Van Hul N, Rudling M, Angelin B, Nowak G, Fischler B, Ellis E.
    J Intern Med; 2020 May 30; 287(5):534-545. PubMed ID: 31976601
    [Abstract] [Full Text] [Related]

  • 16. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease.
    Wunsch E, Milkiewicz M, Wasik U, Trottier J, Kempińska-Podhorodecka A, Elias E, Barbier O, Milkiewicz P.
    Sci Rep; 2015 Aug 21; 5():13462. PubMed ID: 26293907
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Acute caloric restriction counteracts hepatic bile acid and cholesterol deficiency in morbid obesity.
    Straniero S, Rosqvist F, Edholm D, Ahlström H, Kullberg J, Sundbom M, Risérus U, Rudling M.
    J Intern Med; 2017 May 21; 281(5):507-517. PubMed ID: 28261926
    [Abstract] [Full Text] [Related]

  • 20. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.
    Schreuder TC, Marsman HA, Lenicek M, van Werven JR, Nederveen AJ, Jansen PL, Schaap FG.
    Am J Physiol Gastrointest Liver Physiol; 2010 Mar 21; 298(3):G440-5. PubMed ID: 20093562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.